Most Recent Articles by Andrea S. Blevins Primeau, PhD, MBA
Administration restrictions on oral mercaptopurine (6-MP) are unnecessary and may impair adherence among children with ALL.
Study results indicate that although there are significant differences in HRQOL between the United States and Chile, clinical outcomes were similar.
Data suggest that patients whose GIST harbors a KIT exon 11 deletion should receive imatinib for 3 years.
A study identified gaps in behavioral research, including interventions for targets, use of technology, theory, and environmental manipulation to improve intervention.
Study authors attributed some of the increase in testing among low-risk women to lack of knowledge of health care providers regarding the indication of the test.
More Articles by Andrea S. Blevins Primeau, PhD, MBA
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|